Ixazomib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 688 publications
Recent advances in management of systemic AL amyloidosis
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: June 03, 2026
Crescentic Glomerulonephritis in a Patient With AL Amyloidosis: A Case Report.
Journal: Kidney medicine
Published: June 01, 2026
The Impact of Treatment Time Toxicity on Regimen Selection in Multiple Myeloma: A Single-Center Retrospective Study.
Journal: Internal medicine (Tokyo, Japan)
Published: May 24, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia.
Journal: Research square
Published: May 04, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 14, 2026
AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia.
Journal: Molecular cancer
Published: April 13, 2026
Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance.
Journal: Biochemical pharmacology
Published: March 25, 2026
Deubiquitinases in lung cancer: Oncogenic mechanisms, metabolic reprogramming, immune evasion, and therapeutic targeting.
Journal: Pathology, research and practice
Published: March 23, 2026
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 09, 2026
Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase.
Journal: Leukemia research
Published: March 02, 2026
Last Updated: 06/30/2026